Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension results of a randomized controlled trial - Results of a randomized controlled trial

被引：85

作者：

O'Hare, JP ^{[1
]}

Bilous, R ^{[1
]}

Mitchell, T ^{[1
]}

O'Callaghan, CJ ^{[1
]}

Viberti, GC ^{[1
]}

Willoughby, R ^{[1
]}

Riley, J ^{[1
]}

Robinson, AM ^{[1
]}

Reckless, JP ^{[1
]}

Havard, F ^{[1
]}

Sampson, M ^{[1
]}

Lloyd, A ^{[1
]}

Williams, T ^{[1
]}

Vora, J ^{[1
]}

Chattington, P ^{[1
]}

Hampson, K ^{[1
]}

Ibrahim, H ^{[1
]}

Borthwick, L ^{[1
]}

Willoughby, R ^{[1
]}

Viberti, G ^{[1
]}

Russell, C ^{[1
]}

Barnes, D ^{[1
]}

Macklin, A ^{[1
]}

Murphy, E ^{[1
]}

Stephens, E ^{[1
]}

Vincent, J ^{[1
]}

Tindall, H ^{[1
]}

Simpson, H ^{[1
]}

Knowles, E ^{[1
]}

Cunningham, B ^{[1
]}

Simpson, E ^{[1
]}

Bilous, R ^{[1
]}

Bilous, M ^{[1
]}

Mitchell, T ^{[1
]}

O'Halloran, D ^{[1
]}

Nugent, S ^{[1
]}

Hadden, D ^{[1
]}

Fetherstone, M ^{[1
]}

McCarton, D ^{[1
]}

McGurk, C ^{[1
]}

Johnston, C ^{[1
]}

Burton, J ^{[1
]}

Harris, C ^{[1
]}

Hempstead, H ^{[1
]}

Baksi, A ^{[1
]}

Bartlett, J ^{[1
]}

Heaton, C ^{[1
]}

Brown, K ^{[1
]}

Arora, A ^{[1
]}

Burke, J ^{[1
]}

机构：

[1] Univ Warwick, Sch Biol Sci, Sir Quentin Hazel Inst Mol Med, Coventry CV4 7AL, W Midlands, England

来源：

DIABETES CARE | 2000年 / 23卷 / 12期

关键词：

D O I：

10.2337/diacare.23.12.1823

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVE - To assess if low (1.25 mg) and/or standard (5 mg) doses of the ACE inhibitor ramipril could prevent progression of microalbuminuria (incipient diabetic nephropathy) in normotensive type 1 diabetic patients. RESEARCH DESIGN AND METHODS - This study, using a multicenter randomized placebo-controlled double-blind parallel group, was conducted over 2 years in 28 outpatient diabetic clinics in the U.K. and Ireland. We screened 334 type 1 diabetic patients with suspected microalbuminuria and normal blood pressure; of these, 140 patients 18-65 years of age with a diagnosis of type 1 diabetes and persistent microalbuminuria, defined as urinary albumin excretion rate (AER) of 20-200 mug/min, were enrolled in the study. RESULTS - The proportion of patients progressing to macroalbuminuria was reduced in the ramipril groups but did not reach statistical significance over 2 years. AER was significantly lower at year 2 in the combined ramipril-treated patients versus placebo (P = 0.013). More patients on ramipril regressed to normoalbuminuria (<20 <mu>g/min), with 11% for 1.25 mg ramipril, 20% for 5 mg ramipril, and 4% for placebo (P = 0.053). Blood pressure was significantly reduced to a similar extent with both 1.25 and 5 mg ramipril. Supine systolic blood pressure increased from 130 to 134 mmHg in the placebo group and fell in the 1.25 mg ramipril group (from 132 to 129 mmHg) and in the 5 mg ramipril group (from 134 to 130 mmHg) (P = 0.003, compared with placebo). No statistically significant changes were observed in glomerular filtration rate (GFR) between the placebo- and ramipril-treated groups during the 2-year period. CONCLUSIONS - Microalbuminuria is reduced significantly by ramipril treatment in type 1 diabetic patients without hypertension. Although the magnitude of the response was greater, there is no significant difference between responses to 1.25 or 5 mg ramipril. Small but highly significant reductions in systolic and mean arterial pressures occur in ramipril-treated patients. GFR is stable at this stage of the evolution of diabetic nephropathy and is unaffected by ramipril treatment for 2 years.

引用

页码：1823 / 1829

页数：7

共 32 条

[1] ANDERSEN AR, 1978, DIABETOLOGIA, V14, P363
[2] BENEFICIAL-EFFECTS OF ANGIOTENSIN CONVERTING ENZYME-INHIBITION ON RENAL-FUNCTION IN PATIENTS WITH DIABETIC NEPHROPATHY
BJORCK, S
NYBERG, G
MULEC, H
GRANERUS, G
HERLITZ, H
AURELL, M
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1986, 293 (6545): : 471 - 474
[3] RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY
BJORCK, S
MULEC, H
JOHNSEN, SA
NORDEN, G
AURELL, M
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823): : 339 - 343
[4] Bojestig M., 1997, Diabetologia, V40, pA544
[5] Boner G, 1996, DIABETOLOGIA, V39, P587
[6] IOHEXOL CLEARANCE FOR THE DETERMINATION OF GLOMERULAR-FILTRATION RATE IN CLINICAL-PRACTICE - EVIDENCE FOR A NEW GOLD STANDARD
BROWN, SCW
OREILLY, PH
[J]. JOURNAL OF UROLOGY, 1991, 146 (03) : 675 - 679
[7] Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
Chaturvedi, N
Stevenson, J
Fuller, JH
Rottiers, R
Ferriss, B
Karamanos, B
Kofinis, A
Petrou, C
IonescuTirgovisite, C
Iosif, C
Tamas, G
Bibok, G
Kerenyi, Z
KisGombos, P
Toth, J
Grealy, G
Priem, H
Koivisto, V
Tuominen, J
Kostamo, E
IdziorWalus, B
Solnica, B
GalickaLatalie, D
Michel, G
Keipes, M
Giuliani, A
Herode, A
Santeusanio, F
Bueti, A
Bistoni, S
Cagini
Navalesi, R
Penno, G
Nannipieri, M
Rizzo, L
Miccoli, R
Ghirlanda, G
Cotroneo, P
Manto, A
Minella, A
Saponara, C
Ward, J
Plater, M
Ibrahim, S
Ibbotson, S
Mody, C
Papazoglou, N
Manes, C
Soulis, K
Voukias, M
[J]. LANCET, 1997, 349 (9068) : 1787 - 1792
[8] Pathogenesis, prevention, and treatment of diabetic nephropathy
Cooper, ME
[J]. LANCET, 1998, 352 (9123) : 213 - 219
[9] Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure
Crepaldi, G
Carta, Q
Deferrari, G
Mangili, R
Navalesi, R
Santeusanio, F
Spalluto, A
Vanasia, A
Villa, GM
Nosadini, R
[J]. DIABETES CARE, 1998, 21 (01) : 104 - 110
[10] Deckert T, 1984, DIAB NEPHROPATHY, V3, P6

← 1 2 3 4 →